Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

UK Doctors Back Calls For Minimum Price For Alcohol
Doctors attending the BMA"s annual conference in Liverpool have today (Thursday 2 July 2009) backed calls to introduce a minimum price for a unit of alcohol. Proposing a motion which also included calls for clearer labelling and a total ban on alcohol advertising, Dr Chandra Mohan from Barking, Havering and Brentwood, said:
generic viagra online
Politico Examines Retraction, Resubmission Of HHS HIV Immigration Policy
Politico"s Blog "Under the Radar" explores the HHS" recent decision to revise documents submitted to the Federal Register regarding a change in HIV-related immigration policy.
News of the day
Sorin Group Announces Regulatory Approval And First Implants Of New-Platform FACIL And REPLY Pacemakers In Japan
Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced the Ministry of Health, Labor and Welfare (MHLW) approval to market the FACIL™ and REPLY™ families of dual and single chamber rate responsive pacemakers.
Health Insurance

Atrium Medical Receives CE Mark For Its CinatraTM CoCr Coronary Stent System

Atrium Medical is pleased to announce that is has received CE Mark for a new generation Cobalt Chromium Coronary Stent System called Cinatra™. Cinatra™ is indicated for the treatment of coronary artery occlusive disease. Atrium is excited to release this best in class Cobalt Chromium Coronary Stent System that is extremely low in profile, ultra flexible, and highly deliverable. In an independent lab test, Atrium"s new Cinatra™ CoCr Stent was highlighted as having the lowest crossing profile and greatest flexibility when compared to the leading competitors.* The advanced design of the Cinatra™ CoCr Stent with its superior mechanical properties have produced excellent clinical results yielding a very low late lumen loss. Preliminary results from the CONFIRM 1 multi-center prospective trial have shown the Cinatra™ CoCr Stent to have a mean in-stent late lumen loss of 0.69 mm at 6 months. This low late lumen loss is clear evidence that Cinatra™ offers excellent clinical results and will offer cardiologists a new option when treating coronary artery disease. *Data on file at Atrium. Atrium


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009